Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DG 051

Drug Profile

DG 051

Alternative Names: DG-051

Latest Information Update: 30 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator deCODE genetics; Saga Investments
  • Developer deCODE genetics
  • Class Cardiovascular therapies; Pyrrolidines; Small molecules
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Myocardial infarction

Most Recent Events

  • 31 Dec 2012 deCODE genetics has been acquired by Amgen
  • 09 Jan 2008 Adverse events data from a phase IIa trial in myocardial infarction released by deCODE
  • 10 Oct 2007 Phase-II clinical trials in Myocardial infarction in Iceland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top